Note 15- Collaborative and Other Relationships Textual (Details) $ in Thousands						1 Months Ended			2 Months Ended	12 Months Ended				70 Months Ended
	Sep. 15, 2021 USD ($)	Mar. 04, 2020 USD ($)	Nov. 05, 2019 USD ($)	Jun. 16, 2015 USD ($)	Sep. 30, 2013 USD ($)	Aug. 31, 2020 USD ($)	Sep. 30, 2018 USD ($) dose	Jun. 30, 2000 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2022 USD ($) dose	Dec. 31, 2021 USD ($) dose	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($) dose	Mar. 31, 2021 USD ($)	Mar. 31, 2015 USD ($)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total revenues										$ 270,827	$ 157,170	$ 17,812
Arbitration Proceedings of SUL Agreement
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Litigation settlement, amount awarded from other party		$ 5,000
Arbitration Proceedings of SUL Agreement | Other Income
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Gain (loss) related to litigation settlement, total												8,893
Arbitration Proceedings of SUL Agreement | Selling, general and administrative
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Legal fees												5,026
U.S. Department of Health and Human Services
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Collaborative agreement contract value							$ 34,660
Contract term (year)							5 years
U.S. Department of Health and Human Services | RAPIVAB
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Maximum number of products, doses | dose							50,000
Number of product delivered, doses | dose										49,980			20,000
Proceeds from collaborators										$ 13,864	$ 6,918		$ 13,864
Number of additional products, doses | dose										20,000	9,980
Torii Pharmaceutical Co., Ltd.
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total revenues										$ 0
Contract with customer, liability			$ 22,000							22		22
Potential milestone payments receivable if regulatory approval before december 31, 2021			$ 15,000
Maximum customary reduction on royalty rate			50.00%
Royalty payments receivable, expiration term from first commercial (year)			10 years
Revenue from contract with customer, excluding assessed tax									$ 20,101			$ 1,899
Torii Pharmaceutical Co., Ltd. | Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Royalty rate if maintains sakigake designation			20.00%
Torii Pharmaceutical Co., Ltd. | Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Royalty rate if maintains sakigake designation			40.00%
CSL Limited
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Proceeds from license fees received				$ 33,740
Milestone payment received														$ 12,000
Base Contract
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Government contract receivable															$ 16,265
Additional Development Options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Government contract receivable															22,855
ASPRBARDA Contract
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Government contract receivable															$ 39,120
Proceeds from awards for research and development contracts										$ 20,574
AECOM and IRL
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Milestone payment minimum								$ 1,400
Milestone payment maximum								4,000
Annual license fee minimum								150
Annual license fee maximum								$ 500
National Institute of Allergy and Infectious Diseases
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Receivable from awards for research and development contracts	$ 47,315				$ 45,931
Potential aggregate maximum amount of funding						$ 43,908
Collaborative agreement contract value						$ 6,326
UAB
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Period of agreement (year)										25 years
Renewable period of agreement (year)										5 years